JP2024516033A - オレキシン受容体アゴニスト及びその使用 - Google Patents

オレキシン受容体アゴニスト及びその使用 Download PDF

Info

Publication number
JP2024516033A
JP2024516033A JP2023567888A JP2023567888A JP2024516033A JP 2024516033 A JP2024516033 A JP 2024516033A JP 2023567888 A JP2023567888 A JP 2023567888A JP 2023567888 A JP2023567888 A JP 2023567888A JP 2024516033 A JP2024516033 A JP 2024516033A
Authority
JP
Japan
Prior art keywords
alkyl
mmol
compound
cycloalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516033A5 (https=
Inventor
チョバティア，プラフルクマー
ベアート，クラウディア
オウブリー，ジル
マリネッリ，ダビデ
Original Assignee
ジャズ ファーマシューティカルズ アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャズ ファーマシューティカルズ アイルランド リミテッド filed Critical ジャズ ファーマシューティカルズ アイルランド リミテッド
Publication of JP2024516033A publication Critical patent/JP2024516033A/ja
Publication of JP2024516033A5 publication Critical patent/JP2024516033A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023567888A 2021-05-03 2022-05-03 オレキシン受容体アゴニスト及びその使用 Pending JP2024516033A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183321P 2021-05-03 2021-05-03
US63/183,321 2021-05-03
PCT/EP2022/061851 WO2022233872A1 (en) 2021-05-03 2022-05-03 Orexin receptor agonists and uses thereof

Publications (2)

Publication Number Publication Date
JP2024516033A true JP2024516033A (ja) 2024-04-11
JP2024516033A5 JP2024516033A5 (https=) 2025-05-14

Family

ID=81940742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567888A Pending JP2024516033A (ja) 2021-05-03 2022-05-03 オレキシン受容体アゴニスト及びその使用

Country Status (12)

Country Link
US (1) US20240254143A1 (https=)
EP (1) EP4334323A1 (https=)
JP (1) JP2024516033A (https=)
KR (1) KR20240004802A (https=)
CN (1) CN117616030A (https=)
AU (1) AU2022269811A1 (https=)
BR (1) BR112023022050A2 (https=)
CA (1) CA3217403A1 (https=)
IL (1) IL308099A (https=)
MX (1) MX2023012971A (https=)
TW (1) TW202309051A (https=)
WO (1) WO2022233872A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2023081094A1 (en) * 2021-11-04 2023-05-11 University Of Washington Novel spirocyclic compounds as klhdc2 ligands
EP4658660A1 (en) 2023-01-31 2025-12-10 Jazz Pharmaceuticals Ireland Limited Macrocyclic orexin receptor agonists and uses thereof
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
JP2013515033A (ja) * 2009-12-21 2013-05-02 ノバルティス アーゲー オレキシン受容体アンタゴニストとしてのジアザ−スピロ［５．５］ウンデカン類
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2020004537A1 (ja) * 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69318854T2 (de) * 1993-03-04 1998-10-08 Pfizer Spiroazacyclischderivate als substanz p antagonisten
DE69923744T2 (de) * 1998-10-23 2006-02-23 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515033A (ja) * 2009-12-21 2013-05-02 ノバルティス アーゲー オレキシン受容体アンタゴニストとしてのジアザ−スピロ［５．５］ウンデカン類
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2020004537A1 (ja) * 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TETRAHEDRON, vol. 76(3), JPN6026001873, 2020, pages 130842, ISSN: 0005777490 *

Also Published As

Publication number Publication date
MX2023012971A (es) 2024-01-16
AU2022269811A1 (en) 2023-11-16
BR112023022050A2 (pt) 2023-12-26
US20240254143A1 (en) 2024-08-01
EP4334323A1 (en) 2024-03-13
CN117616030A (zh) 2024-02-27
KR20240004802A (ko) 2024-01-11
WO2022233872A1 (en) 2022-11-10
TW202309051A (zh) 2023-03-01
IL308099A (en) 2023-12-01
CA3217403A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JP2024516033A (ja) オレキシン受容体アゴニスト及びその使用
US10711020B2 (en) Tricyclic sulfones as RORγ modulators
AU2022214618A1 (en) Cdk2 inhibitors and methods of using the same
EP4132650A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
US20240360081A1 (en) Sulfonamide orexin receptor agonists and uses thereof
JP2026503035A (ja) 新規な可逆性ｄｐｐ１阻害剤及びその用途
US20260042755A1 (en) Gpr6 inverse agonists
TW202412784A (zh) 氮-喹唑啉化合物及使用方法
EP4048677A1 (en) Progranulin modulators and methods of using the same
JP2025518216A (ja) 大環状オレキシン受容体アゴニスト及びその使用
TW202444724A (zh) 大環食慾激素受體促效劑及其用途
WO2024020156A1 (en) Emopamil-binding protein inhibitors and uses thereof
TW202508566A (zh) Kv1.3鉀通道拮抗劑
HK40029777A (en) Receptor inhibitor, pharmaceutical composition comprising same, and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260421